Real-world evidence on NSCLC treatment patterns and outcomes showcases Flatiron’s unified, global oncology engine
NEW YORK–(BUSINESS WIRE)–Flatiron Health today announced its presence at the IASLC 2026 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, with three research acceptances highlighting real-world evidence that advances precision medicine and treatment optimization in non-small cell lung cancer (NSCLC). The presentations demonstrate how Flatiron’s high-quality, longitudinal data reveals clinical insights that shape oncology decision-making across the globe.
“Recent advances have fundamentally transformed treatment options for lung cancers, and our research highlights where and when these novel treatments are having an impact for patients in real-world practice,” said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. “Our WCLC research, spanning disease states, biomarker-defined subgroups, and treatment types, illuminates how to translate innovation into practice. By capturing this real-world complexity at scale through our Panoramic Database, we’re generating the evidence needed to guide clinicians in a rapidly evolving treatment landscape—enabling them to deliver personalized medicine to any patient that is in front of them.”
Flatiron’s research at WCLC 2026 underscores the company’s position as the gold standard in oncology intelligence, delivering the trusted insights needed to guide the highest-stakes decisions in cancer care and drug development.
Research highlights include:
- Genomic alterations without approved first-line targeted therapies in patients with NSCLC PD-L1 ≥50% treated with immunotherapy: Real-world evidence revealing treatment patterns and outcomes for patients with high PD-L1 expression who lack approved targeted therapy options, demonstrating how immunotherapy is being deployed in clinical practice and informing precision medicine strategies.
- Real-world outcomes with chemoradiation and durvalumab consolidation in stage III KRAS G12C–mutant NSCLC in the US: Examining real-world treatment effectiveness and durability of durvalumab consolidation following chemoradiation in patients with stage III KRAS G12C-mutant disease, providing evidence on how emerging targeted approaches are translating to clinical outcomes.
- Real-world treatment duration and outcomes among patients with early-stage NSCLC receiving adjuvant osimertinib: A retrospective cohort study analyzing treatment patterns, adherence, and survival outcomes in early-stage NSCLC patients receiving adjuvant osimertinib, revealing how precision medicine is reshaping the adjuvant treatment landscape.
These findings underscore Flatiron’s ability to transform patient experiences into actionable intelligence—connecting evidence to practice and enabling clinicians and researchers to make clearer decisions that drive better outcomes.
Join Flatiron Health at WCLC 2026 and follow Flatiron Health on X and LinkedIn for more updates.
Abstracts and Poster Presentations
Genomic alterations without approved 1L targeted therapies in patients with NSCLC PD-L1 ≥50% treated with immunotherapy
J.W. Riess, S. Viswanathan, S.K. Mhatre, S. Ding, I.K. Dhillon, S. Lambert, X. Ma, B. Herzberg
Author Affiliations: UC Davis Comprehensive Cancer Center, Gilead Sciences, Flatiron Health, Columbia University
Session: P1.106-234. Resectable NSCLC (Stages I–III)
Date/Time: Sunday, September 13, 2026 at 10:30 AM KST / UTC +9; 1h 30m
Location: Exhibits and Posters, Hall C, 3F
Real-world outcomes with chemoradiation and durvalumab consolidation in stage III KRAS G12C–mutant NSCLC in the US
D. Bruno, K. Sheffield, A. Brnabic, Q. Ma, R. Singh, K. Thoele, T. Puri, C.F. Avile, K. Schwed, M. Bye, A.M. Mehta, M. Pesavento
Author Affiliations: City of Hope Cancer Center, Eli Lilly and Company, Flatiron Health
Session: P2.249-276. Unresectable NSCLC (Stages I–III)
Date/Time: Monday, September 14, 2026 at 10:30 AM KST
Location: Exhibits and Posters, Hall C, 3F
Real-world treatment duration and outcomes among patients with early-stage NSCLC receiving adjuvant osimertinib: a retrospective cohort study
E. Singhi, X. Ma, C. Rinaldi, L. Kovacevic, Y. Liang, D. Simmons, M. Lupicka, I. Arslan, M. Sandelin, J. Pye, D. Nguyen
Author Affiliations: The University of Texas MD Anderson Cancer Center, Flatiron Health, AstraZeneca, City of Hope
Date/Time: Tuesday, September 15, 2026 at 11:55 AM KST
Location: Exhibits and Posters, Hall C, 3F
About Flatiron
Flatiron Health transforms cancer care and research through a unified, global oncology engine powered by expert-validated AI and deep clinical and scientific expertise. Built from the experiences of millions of patients across the US, UK, Germany, and Japan, our real-world evidence informs the research, regulatory, commercial, and treatment decisions shaping oncology today. In the US, our point-of-care technology empowers clinicians to deliver smarter, more connected care while generating deeper insights that help advance cancer research. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth
Contacts
Media Contact
Nina Toor
[email protected]
